SCHEMBL4285341

SCHEMBL4285341

COC[C@]1(O)CCCC[C@H]1n1cnc(C(=O)N2CCN(Cc3ccccc3)C[C@H]2Cc2ccccc2Oc2ccccc2)c1-c1ccccc1

nearest known ligand 0.33

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CA1 P00915 2/20 0.33
CA2 P00918 2/20 0.33
CA4 P22748 2/20 0.33
CA9 Q16790 2/20 0.33
CCR8 P51685 6/20 0.33
KCNH2 Q12809 5/20 0.33
MGLL Q99685 2/20 0.32
HCRTR1 O43613 3/20 0.32
HCRTR2 O43614 3/20 0.32
KDM4E B2RXH2 2/20 0.32
DPP4 P27487 1/20 0.32
DPP7 Q9UHL4 1/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
BCHE P06276 1/20 0.31
ACHE P22303 1/20 0.31
ROCK1 Q13464 1/20 0.30
TRPC6 Q9Y210 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4294545 0.94 SIGMAR1 (0.36) CA1CA2CA4CA9HCRTR1
SCHEMBL4291276 0.94 SIGMAR1 (0.36) CA1CA2CA4CA9HCRTR1
SCHEMBL4289813 0.91 CA1 (0.35) CA1CA2CA4CA9HCRTR2
SCHEMBL4284797 0.91 CA1 (0.35) CA1CA2CA4CA9HCRTR2
SCHEMBL4288504 0.90 CA1 (0.36) CA1CA2CA4CA9DPP4
SCHEMBL4291531 0.88 SIGMAR1 (0.37) CA1CA2CA4CA9KDM4E
SCHEMBL4289702 0.88 HCRTR1 (0.38) CA1CA2CA4CA9HCRTR1
SCHEMBL4290284 0.87 CA1 (0.32) CA1CA2CA4CA9DPP4
SCHEMBL4281681 0.87 CA1 (0.42) CA1CA2CA4CA9MEN1
SCHEMBL13705409 0.86 USP19 (0.36) KCNH2HCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227560-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 US disclosed
US-20090227560-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 US disclosed
US-20090156612-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed
US-20090156612-A1 Substituted imidazole compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156612-A1 Substituted imidazole compound and use thereof REN, ACE, AGT CA1 2275/4885CA2 218/4885CA4 296/4885
US-20090227560-A1 Substituted imidazole compound and use thereof REN, ACE, AGT CA1 2275/4885CA2 218/4885CA4 296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.